Skip to content
Screener

Mirum Pharmaceuticals, Inc. MIRM Other Income (Expense)

Other Income (Expense) at other companies

Gilead Sciences logo
Gilead SciencesGILD
$387M+86.1%
Rhythm Pharmaceuticals, Inc. logo
Rhythm Pharmaceuticals, Inc.RYTM
-$2.73M-13.2%
LQD
Liquidia CorporationLQDA
-$4.72M-60.5%
ALN
Alnylam PharmaceuticalsALNY
-$53.64M-180%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
-$60.6M+7.1%
Arrowhead Research logo
Arrowhead ResearchARWR
$3.7M+132%

Other financials

Income statement

See full
Revenue$176.2M+37.9%
Operating income-$42.5M-753%
Net income-$67.2M-1,047%
EPS (diluted)-$1.06-783%

Balance sheet

See full
Cash & equivalents$262.7M+39.4%
Total debt$12.9M+29.2%
Total equity-$10.4M-104%
Total assets$1.0B+44.0%

Cash flow

See full
Operating cash flow-$44.3M-468%
CapEx$23.0K-81.7%
Free cash flow-$44.3M-472%

Valuation

See full
Market cap$6.45B+144%
Enterprise value$6.2B+151%
P/S10.4×+4.3×

Profitability

See full
Operating margin-134.9%-151pp
Net margin-139.2%-156pp
FCF margin-37%

Returns & leverage

See full
Return on equity-335.8%-377pp
Debt / equity0.1×0.0×
Current ratio2.9×-0.3×

Where this comes from

Reported directly by Mirum Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OtherNonoperatingIncomeExpense.

The source filing: Mirum Pharmaceuticals, Inc.’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:06 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001759425-26-000045
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Other income (expense):
Interest income3,8513,0337,2526,056
Interest expense(2,618)(3,589)(6,234)(7,185)
Other (expense) income, net(24,234)86(24,234)2,194
Net loss before provision for income taxes(65,538)(5,459)(855,218)(19,107)
Provision for income taxes1,6894022,1641,431
Net loss$(67,227)$(5,861)$(857,382)$(20,538)
Net loss per share, basic and diluted$(1.06)$(0.12)$(14.03)$(0.42)

Item 1. Financial Statements (Unaudited)

FAQ

What is Mirum Pharmaceuticals, Inc.'s other income (expense)?
Mirum Pharmaceuticals, Inc. (MIRM) reported other income (expense) of -$24.23M in Q2 2026.
How has Mirum Pharmaceuticals, Inc.'s other income (expense) changed year-over-year?
Mirum Pharmaceuticals, Inc.'s other income (expense) decreased by 28279.1% year-over-year, from $86K to -$24.23M.
What is the long-term trend for Mirum Pharmaceuticals, Inc.'s other income (expense)?
Over 3 years (2021 to 2025), Mirum Pharmaceuticals, Inc.'s other income (expense) has grown at a 64.5% compound annual growth rate (CAGR), from -$582K to $2.59M.
What does other income (expense) mean?
Net total of all non-operating income and expenses not classified in specific line items — a catch-all for miscellaneous financial items.

Ask your AI about Mirum Pharmaceuticals, Inc.'s other income (expense).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude